Psychedelic drug

Heroic Dose Event Explores Promise of Psychedelic Medicine for Veterans, Military & Servicemen and Women

Thursday, April 8, 2021 - 1:00pm

Toronto, Ontario--(Newsfile Corp. - April 8, 2021) - Microdose Psychedelic Insights , along with Entheon Biomedical Corp. , Bexson Biomedical , HavnLife and The Conscious Fund , present the Heroic Dose .

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - April 8, 2021) - Microdose Psychedelic Insights , along with Entheon Biomedical Corp. , Bexson Biomedical , HavnLife and The Conscious Fund , present the Heroic Dose .
  • The Heroic Dose will commence on 22nd April at 8:45 am EST.
  • This one-day virtual conference explores the use of psychedelic therapies for military veterans and first responders in an effort to combat the alarming rates of PTSD, substance abuse and suicide in this valuable yet underserved demographic.
  • This conference will feature some of the finest Navy SEAL and national security professionals, veterans and other servicemen and women, along with knowledgeable experts in psychedelic therapy, researchers, clinicians, companies, advocates.

AIkido Granted Sublicense to Technology for Targeted Psilocybin Treatment of Neuro-Inflamed Tissue in Cancer Patients

Wednesday, April 7, 2021 - 2:00pm

The homing peptides covered by the sublicense can be used to facilitate the delivery of therapeutic agents to inflamed CNS tissue.

Key Points: 
  • The homing peptides covered by the sublicense can be used to facilitate the delivery of therapeutic agents to inflamed CNS tissue.
  • Anthony Hayes, CEO of AIkido Pharma, stated, "The novel homing peptides covered under this sublicense have the potential to allow the direct delivery of psilocybin to inflamed CNS tissue in cancer patients.
  • It complements our recently announced support of the psilocybin research for PTSD treatment at Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research."
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics.

NeonMind Developing Music Playlist for Psychedelic Therapy Sessions

Tuesday, April 6, 2021 - 11:00am

Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) (OTC PINK: NMDBF) ("NeonMind"), is pleased to announce the commencement of a three phase university study dedicated to creating an ideal music playlist to accompany therapeutic psychedelic sessions.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) (OTC PINK: NMDBF) ("NeonMind"), is pleased to announce the commencement of a three phase university study dedicated to creating an ideal music playlist to accompany therapeutic psychedelic sessions.
  • Previous research has established that music for a therapeutic psychedelic session can significantly impact the experience.
  • To view an enhanced version of Figure 1, please visit:
    "The emotional arc of a musical playlist during a psychedelic session can play an important role in supporting someone's therapeutic experience," says Rob Tessarolo, President & CEO of NeonMind.
  • For more information on NeonMind, go to www.NeonMindBiosciences.com or buy NeonMind mushroom infused coffee at www.NeonMind.com .

Mindset Pharma Announces Filing of Amended and Restated FS and MD&A for the Three and Six Month Period Ended December 31, 2020

Friday, April 2, 2021 - 3:28am

Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.

Key Points: 
  • Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.
  • Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.
  • www.mindsetpharma.com
    This news release contains certain "forward-looking information" within the meaning of applicable securities law.
  • The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change, unless required by law.

Psirenity signs partnership with Jamaica’s Scientific Research Council to conduct joint studies into beneficial effects of psilocybin mushrooms

Thursday, April 1, 2021 - 1:00pm

TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Psirenity, a wholly owned subsidiary of New Leaf Canada Inc., today announced it has signed a two-year partnership with Jamaicas Scientific Research Council (SRC) to conduct cooperative studies into the beneficial effects of psilocybin mushrooms.

Key Points: 
  • TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Psirenity, a wholly owned subsidiary of New Leaf Canada Inc., today announced it has signed a two-year partnership with Jamaicas Scientific Research Council (SRC) to conduct cooperative studies into the beneficial effects of psilocybin mushrooms.
  • Under the new partnership, SRC, Jamaicas principal public sector agency responsible for scientific research and development, will provide technical support, technology transfer and physical and human resources that will allow Psirenity to develop imaginative new mental health treatments.
  • This new collaboration will help Psirenity streamline and scale-up production of psilocybin mushrooms to develop critical nutraceutical and pharmaceutical products, McCullough said.
  • Psirenity believes creating advanced psilocybin therapies for mental health and offering proprietary psycho-educational programs, as well as evidence-based therapeutics and nutraceuticals, can help advance human achievement through enhanced psychedelics.

Psychedelics Companies are Establishing Core IPs in Growing Market

Wednesday, March 31, 2021 - 1:58pm

These key developments have put more eyes than ever before on psychedelics, and a rush of companies are looking to enter the market.

Key Points: 
  • These key developments have put more eyes than ever before on psychedelics, and a rush of companies are looking to enter the market.
  • Pure Extracts will be one of the first companies in the commercial extraction space to utilize this technology.
  • Aikido's CEO commented in the company's release that the company sees psychedelics as an expanding area of treatment.
  • The psychedelics industry has reached a critical point of development where companies have an opportunity to establish themselves as key players in a surging market, and companies like Pure Extracts are timing their own developments to do just that.

Psychedelics Companies are Establishing Core IPs in Growing Market

Wednesday, March 31, 2021 - 2:00pm

These key developments have put more eyes than ever before on psychedelics, and a rush of companies are looking to enter the market.

Key Points: 
  • These key developments have put more eyes than ever before on psychedelics, and a rush of companies are looking to enter the market.
  • Pure Extracts will be one of the first companies in the commercial extraction space to utilize this technology.
  • Aikido's CEO commented in the company's release that the company sees psychedelics as an expanding area of treatment.
  • The psychedelics industry has reached a critical point of development where companies have an opportunity to establish themselves as key players in a surging market, and companies like Pure Extracts are timing their own developments to do just that.

Why Mainstream Mental-Health Care is Embracing Psilocybin - Alternative Active Substances

Wednesday, March 31, 2021 - 1:30pm

While the study of psychedelics as medicine, all across the globe, is inching toward the mainstream, it still remains somewhat controversial.

Key Points: 
  • While the study of psychedelics as medicine, all across the globe, is inching toward the mainstream, it still remains somewhat controversial.
  • A recent article on WIRED (UK) projected that Psychedelic medicine will begin to cross over into the mental health mainstream in 2021.
  • "In both Europe and the US, medicines regulators have eased restrictions on using MDMA to treat post-traumatic disorder (PTSD), and on psilocybin the active substance in magic mushrooms to treat depression.
  • In the UK, London-based mental-health care company COMPASS Pathways has raised more than $115m to fund its efforts and bring to market a psilocybin treatment for depression.

Why Mainstream Mental-Health Care is Embracing Psilocybin - Alternative Active Substances

Wednesday, March 31, 2021 - 1:30pm

While the study of psychedelics as medicine, all across the globe, is inching toward the mainstream, it still remains somewhat controversial.

Key Points: 
  • While the study of psychedelics as medicine, all across the globe, is inching toward the mainstream, it still remains somewhat controversial.
  • A recent article on WIRED (UK) projected that Psychedelic medicine will begin to cross over into the mental health mainstream in 2021.
  • "In both Europe and the US, medicines regulators have eased restrictions on using MDMA to treat post-traumatic disorder (PTSD), and on psilocybin the active substance in magic mushrooms to treat depression.
  • In the UK, London-based mental-health care company COMPASS Pathways has raised more than $115m to fund its efforts and bring to market a psilocybin treatment for depression.

The First Psychedelic Medicine Clinic Opens in Minnesota

Monday, March 29, 2021 - 1:23pm

The first psychedelic-assisted therapy clinic in Minnesota, called the Institute for Integrative Therapies (IIT), opens its new St. Paul clinic May 1st (after completing a soft opening that ran between July 2020-March 2021), laying a foundation for the coming psychedelic renaissance in the field of mental health.

Key Points: 
  • The first psychedelic-assisted therapy clinic in Minnesota, called the Institute for Integrative Therapies (IIT), opens its new St. Paul clinic May 1st (after completing a soft opening that ran between July 2020-March 2021), laying a foundation for the coming psychedelic renaissance in the field of mental health.
  • Currently, Ketamine is the only legal substance used for these therapies in most states, including the state of Minnesota.
  • IIT is a company that delivers psychedelic medicine safely and ethically with the goal of helping Minnesotans find new ways to approach their lives.
  • Dr. Manoj Doss is the board-certified, medical director for IIT, and a leader in the emerging field of Psychedelic Assisted Psychotherapy.